Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics (Nasdaq: PSTV), recently joined Daniel Levine, host of The Bio Report podcast by Levine Media Group, to discuss the challenges of treating brain tumors, the limitations of current therapies, and how Plus Therapeutics’ targeted radiotherapies are designed to create better outcomes for patients with central nervous system (CNS) cancers.
In this insightful episode, Dr. Hedrick highlights the urgent need for innovative therapies to address aggressive brain tumors, where traditional treatments often fail to provide meaningful long-term results. He explains how Plus Therapeutics’ radiotherapeutic platforms are engineered to precisely deliver radiation directly to the tumor site, potentially reducing damage to healthy brain tissue and improving patient outcomes.
“Brain tumors remain one of the most challenging cancers to treat effectively,” said Marc Hedrick, M.D. “Our mission is to use advanced radiotherapy technologies to improve precision, minimize toxicity, and ultimately help patients live longer, better lives.”
Advancing Targeted Radiotherapies for CNS Cancers
Plus Therapeutics is pioneering novel targeted radiotherapies to address difficult-to-treat brain and spinal tumors, including leptomeningeal metastases and other aggressive CNS cancers. By combining innovative delivery platforms with highly selective radiation isotopes, the company aims to:
-
Increase tumor targeting precision while sparing healthy tissue
-
Overcome barriers that limit the effectiveness of conventional therapies
-
Improve safety profiles and patient outcomes for some of the most complex cancers
Listen to the Full Podcast
Listen to the full episode with Marc Hedrick, M.D.: Click Here
Learn more about Plus Therapeutics and our clinical research: Respect Trials Official Site
Investor Relations — Plus Therapeutics (Nasdaq: PSTV): Visit IR Site →
#PlusTherapeutics #Radiotherapy #BrainTumors #CNSCancers #CancerResearch #PrecisionRadiotherapy #NeuroOncology #PSTV #LevineMediaGroup #TheBioReport
Recent Comments